ABIVAX (EPA:ABVX) | WebDisclosure

PRESS RELEASE

published on 10/03/2024 at 22:01, 1 month 19 days ago

Abivax annonce le recrutement d'un premier patient dans Enhance-CD, l'essai clinique de phase 2b avec obefazimod dans la maladie de Crohn
Abivax recrute premier patient pour Enhance-CD, essai clinique phase 2b obefazimod maladie Crohn. Etude 3 phases. Obefazimod, traitement prometteur

Abivax Obefazimod Maladie De Crohn Essai Clinique Enhance-CD
BRIEF

published on 10/03/2024 at 08:35, 1 month 20 days ago

Abivax annonce des résultats positifs pour l'obéfazimod dans le traitement de la rectocolite hémorragique

Abivax Obefazimod Rectocolite Hémorragique Étude Clinique Analyse De Sécurité
BRIEF

published on 10/03/2024 at 08:35, 1 month 20 days ago

Abivax Announces Positive Results for Obefazimod in Ulcerative Colitis Treatment

Abivax Obefazimod Ulcerative Colitis Clinical Study Safety Analysis
PRESS RELEASE

published on 10/03/2024 at 08:30, 1 month 20 days ago

Résultats positifs d'une analyse intermédiaire portant sur l'efficacité et la tolérance d’obefazimod 25 mg chez des patients atteints de RCH modérée à sévère après deux ans de maintenance en ouvert
Abivax annonce des résultats positifs pour obefazimod 25 mg chez les patients atteints de RCH modérée à sévère après 2 ans de maintenance. Analyse intermédiaire d'une étude de 6 ans

Abivax Obefazimod Efficacité RCH Rémission Clinique
PRESS RELEASE

published on 10/03/2024 at 08:30, 1 month 20 days ago

Résultats positifs d'une analyse intermédiaire portant sur l'efficacité et la tolérance d’obefazimod 25 mg chez des patients atteints de RCH modérée à sévère après deux ans de maintenance en ouvert
Abivax annonce des résultats positifs d'une analyse intermédiaire sur l'efficacité d'obefazimod 25 mg pour les patients atteints de RCH modérée à sévère après 2 ans de traitement

Abivax Obefazimod Efficacité Tolérance RCH Modérée
PRESS RELEASE

published on 10/03/2024 at 08:30, 1 month 20 days ago

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
Abivax announces positive interim results of obefazimod in ulcerative colitis patients after 2 years, showing maintenance of remission and safety profile consistency

Abivax Obefazimod Ulcerative Colitis Safety Efficacy
BRIEF

published on 09/26/2024 at 08:35, 1 month 27 days ago

Abivax présentera trois résumés sur l'obéfazimod dans la rectocolite hémorragique lors de la semaine UEG 2024

Abivax Obefazimod Rectocolite Hémorragique Étude De Phase 2b Semaine UEG 2024
BRIEF

published on 09/26/2024 at 08:35, 1 month 27 days ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Abivax Obefazimod Ulcerative Colitis Phase 2b Study UEG Week 2024
PRESS RELEASE

published on 09/26/2024 at 08:30, 1 month 27 days ago

Abivax annonce la présentation de trois abstracts sur Obefazimod dans la rectocolite hémorragique lors du congrès UEG Week 2024
Abivax annonce la présentation de trois abstracts sur Obefazimod dans la rectocolite hémorragique lors du congrès UEG Week 2024. Les présentations mettent en lumière l'efficacité et la sécurité du traitement

Abivax Obefazimod Phase 2b Rectocolite Hémorragique UEG Week
PRESS RELEASE

published on 09/26/2024 at 08:30, 1 month 27 days ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Abivax to present Phase 2b trial results of obefazimod in ulcerative colitis at UEG Week 2024, showcasing efficacy and safety data for potential oral therapy

Abivax Obefazimod Ulcerative Colitis Clinical Trial UEG Week 2024

Published on 11/22/2024 at 23:55, 14 hours 22 minutes ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 14 hours 47 minutes ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 15 hours 12 minutes ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 15 hours 12 minutes ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 15 hours 47 minutes ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 20 hours 3 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 20 hours 17 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 20 hours 24 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 21 hours 22 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 22 hours 17 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 17:45, 20 hours 32 minutes ago

IMMERSION : RFA 2023/2024
Published on 11/22/2024 at 16:15, 22 hours 2 minutes ago

NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/22/2024 at 14:35, 23 hours 42 minutes ago

Communiqué de presse Thales
Published on 11/22/2024 at 14:35, 23 hours 42 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 7 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio

View all LES ECHOS COMFI WIRE

News